Author details

Full Name

Colin R Goding

Affiliation

Ludwig Institute for Cancer Research, University of Oxford

ORCID

Career Start Year

1983

Papers

185

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37972124	Single-cell profiling of MC1R-inhibited melanocytes.	Pigment Cell Melanoma Res	2024
37953065	TFE3 promotes ferroptosis in melanoma.	Pigment Cell Melanoma Res	2024
36701140	AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis.	Cancer Res	2023
37770430	Acetylation reprograms MITF target selectivity and residence time.	Nat Commun	2023
37090624	Loss of MC1R signaling implicates TBX3 in pheomelanogenesis and melanoma predisposition.	bioRxiv	2023
37410595	The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2.	Cell Rep	2023
37131595	DNA damage-induced interaction between a lineage addiction oncogenic transcription factor and the MRN complex shapes a tissue-specific DNA Damage Response and cancer predisposition.	bioRxiv	2023
36812891	An adverse tumor-protective effect of IDO1 inhibition.	Cell Rep Med	2023
34362555	MC1R Functions, Expression, and Implications for Targeted Therapy.	J Invest Dermatol	2022
35771179	The MITF regulatory network in melanoma.	Pigment Cell Melanoma Res	2022
35912100	Connecting Metabolic Rewiring With Phenotype Switching in Melanoma.	Front Cell Dev Biol	2022
36055199	Sublethal cytochrome c release generates drug-tolerant persister cells.	Cell	2022
34958806	Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.	J Invest Dermatol	2022
32548785	Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development".	Handb Exp Pharmacol	2021
33744299	TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF.	J Invest Dermatol	2021
33789714	MITF induces escape from innate immunity in melanoma.	J Exp Clin Cancer Res	2021
34819350	TBX2 controls a proproliferative gene expression program in melanoma.	Genes Dev	2021
34560251	TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.	Pharmacol Res	2021
34140478	BRN2 is a non-canonical melanoma tumor-suppressor.	Nat Commun	2021
34001865	The protective role of MC1R in chromosome stability and centromeric integrity in melanocytes.	Cell Death Discov	2021
34083536	Establishment of a fluorescent reporter of RNA-polymerase II activity to identify dormant cells.	Nat Commun	2021
33262465	Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.	Oncogene	2021
31595650	ABCB5 is activated by MITF and Î²-catenin and is associated with melanoma differentiation.	Pigment Cell Melanoma Res	2020
31733993	Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.	Mol Cell	2020
33396270	Acriflavine, a Potent Inhibitor of HIF-1Î±, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-Hypoxic Conditions.	Cancers (Basel)	2020
32603375	Paradoxical activation of AMPK by glucose drives selective EP300 activityÂ in colorectal cancer.	PLoS Biol	2020
32978520	The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.	Oncogene	2020
32531246	A Reply to ''Evidence that STK19 Is Not an NRAS-Dependent Melanoma Driver".	Cell	2020
32531202	Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.	Mol Cell	2020
30581118	Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming.	Cell Metab	2019
31881017	The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor.	PLoS Genet	2019
31207090	MITF controls the TCA cycle to modulate the melanoma hypoxia response.	Pigment Cell Melanoma Res	2019
31575676	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.	Genes Dev	2019
30712867	Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.	Cell	2019
31123060	MITF-the first 25 years.	Genes Dev	2019
30804224	BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.	Genes Dev	2019
30787281	Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads.	Nat Commun	2019
29235563	Cell and molecular biology: a new section joins the fight against cancer.	Br J Cancer	2018
29992949	A TFEB nuclear export signal integrates amino acid supply and glucose availability.	Nat Commun	2018
30150413	BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.	Proc Natl Acad Sci U S A	2018
29541918	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.	Acta Neuropathol	2018
29786078	Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.	Oncogene	2018
29343685	The protective role of DOT1L in UV-induced melanomagenesis.	Nat Commun	2018
27748762	Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.	Oncogene	2017
28096186	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.	Genes Dev	2017
28119061	NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.	EBioMedicine	2017
29207255	Macrophage Cytoplasmic Transfer in Melanoma Invasion.	Dev Cell	2017
29180744	Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.	Nat Commun	2017
28584020	KIT<sup>D816V</sup> Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma.	Mol Cancer Res	2017
28869973	Palmitoylation-dependent activation of MC1R prevents melanomagenesis.	Nature	2017

1 - 50 of 185

Richard Mitter

The Francis Crick Institute

Career Start Year 2008

Number of shared co-authors 1

M Raza Zaidi

Northwell Health Cancer Institute

Career Start Year 2006

Number of shared co-authors 13

Maggie Cam

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 2005

Number of shared co-authors 1

Andrew V Kossenkov

The Wistar Institute

Career Start Year 2003

Number of shared co-authors 3

Ina Poser

Max Planck Institute of Molecular Cell Biology and Genetics

Career Start Year 2001

Number of shared co-authors 1

Jan Koster

Amsterdam University Medical Centers location AMC

Career Start Year 1999

Number of shared co-authors 2

Robert L Walker

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1997

Number of shared co-authors 1

Agnes Viale

Memorial Sloan Kettering Cancer Center

Career Start Year 1996

Number of shared co-authors 0

Celio Pouponnot

Institut Curie

Career Start Year 1993

Number of shared co-authors 1

Pedro Aza-Blanc

Sanford-Burnham-Prebys Medical Discovery Institute

Career Start Year 1993

Number of shared co-authors 5

Ashani T Weeraratna

Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine

Career Start Year 1992

Number of shared co-authors 7

Marcus Bosenberg

Yale School of Medicine

Career Start Year 1992

Number of shared co-authors 13

Jeffrey J Delrow

Clinical Research Division, Fred Hutchinson Cancer Research Center

Career Start Year 1992

Number of shared co-authors 0

Peter D Adams

Sanford Burnham Prebys Medical Discovery Institute

Career Start Year 1991

Number of shared co-authors 3

Glenn S Cowley

Broad Institute of Harvard and MIT

Career Start Year 1990

Number of shared co-authors 0

Rod Bremner

University of Toronto

Career Start Year 1990

Number of shared co-authors 1

Dirk Geerts

Amsterdam University Medical Center

Career Start Year 1989

Number of shared co-authors 0

Thomas J Hornyak

University of Maryland School of Medicine

Career Start Year 1989

Number of shared co-authors 2

Kristian Helin

The Institute of Cancer Research

Career Start Year 1988

Number of shared co-authors 2

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 3

Anthony E Oro

Stanford University

Career Start Year 1985

Number of shared co-authors 0

Stephen J Elledge

Howard Hughes Medical Institute, Brigham and Women's Hospital, Harvard Medical School

Career Start Year 1982

Number of shared co-authors 2

Alan Ashworth

UCSF Helen Diller Family Comprehensive Cancer Center

Career Start Year 1982

Number of shared co-authors 5

Edison T Liu

USA The Jackson Laboratory Cancer Center

Career Start Year 1982

Number of shared co-authors 1

Francisca Vazquez

Broad Institute of MIT and Harvard

Career Start Year 1979

Number of shared co-authors 2

Alexander Kamb

Inc. 30301 Agoura Rd.

Career Start Year 1979

Number of shared co-authors 0

Glenn Merlino

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1978

Number of shared co-authors 16

Stephen H Friend

University of Oxford

Career Start Year 1978

Number of shared co-authors 3

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Career Start Year 1974

Number of shared co-authors 16

Norman E Sharpless

National Cancer Institute

Career Start Year 1945

Number of shared co-authors 3

row(s) 1 - 30 of 30